P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Key facts
- Who runs it
- Poseida Therapeutics, Inc.
- Where
- Baltimore, Boston, Denver, Duarte, Nashville, New Orleans, New York, San Diego, and San Francisco, United StatesSee the 10 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 40 people enrolled
- Started
- 28 Feb 2020
- Ended
- 30 Sept 2024
- Type of study
- Interventional, 4 groups
- Treatments tested
- P-PSMA-101 CAR-T cells
- Rimiducid
- Record updated
- 17 February 2025
- Why it stopped
- Study closed
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Subjects ≥18 years of age
- Must have a confirmed diagnosis of mCRPC or SGC
- Must have measurable disease by RECIST 1.1 or bone only metastases with measurable PSA (≥1 ng/mL) (mCRPC subjects only)
- Must have progressed by PCWG3 and/or RECIST 1.1 (mCRPC subjects only)
- Must be willing to practice birth control from screening and for 2 years after the last administration of P-PSMA-101
- Must have adequate vital organ function within pre-determined parameters
- Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
Who cannot take part
- Has received anti-cancer medications (excluding GnRH targeted therapies) within 2 weeks of the time of initiating conditioning chemotherapy
- Has received immunosuppressive medications (including anti-cancer medications) within 2 weeks of initiating leukapheresis and/or expected to require them while enrolled in the study
- Has received systemic corticosteroid therapy within 2 weeks of either the required leukapheresis or is expected to require it during the course of the study
- Has an active second malignancy in addition to mCRPC or SGC, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell skin carcinoma
- Has a history of or active autoimmune disease
- Has a history of significant central nervous system (CNS) disease, such as stroke or epilepsy
- Has an active systemic (viral, bacterial or fungal) infection
- Has a history of significant ocular disease
- Has a history of significant liver disease or active liver disease
- Has a history of or known predisposition to HLH or MAS
- Has inadequate venous access and/or contraindications to leukapheresis
- Has CNS metastases or symptomatic CNS involvement
- Has liver metastases (<5 lesions and maximum diameter </= 2.5 cm permitted)
Where in United States
- University of Maryland, BaltimoreBaltimore, United States
- Dana-Farber Cancer InstituteBoston, United States
- Massachusetts General HospitalBoston, United States
- Sarah Cannon Research Institute at HealthONEDenver, United States
- City of Hope Comprehensive Cancer CenterDuarte, United States
- Tennessee OncologyNashville, United States
- Tulane University Hospital and ClinicNew Orleans, United States
- Memorial Sloan-Kettering Cancer CenterNew York, United States
- University of California San DiegoSan Diego, United States
- University of California San FranciscoSan Francisco, United States
About the trial
What the trial wants to find out
An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.
The 4 groups in the trial
- P-PSMA-101 CAR-T cells (Single Dose - Part 1a)Treatment being tested
Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen A. Rimiducid may be administered as indicated.
Treatment: P-PSMA-101 CAR-T cells and Rimiducid
- P-PSMA-101 CAR-T cells (Multiple Dose - Part 1b)Treatment being tested
Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen A. Rimiducid may be administered as indicated.
Treatment: P-PSMA-101 CAR-T cells and Rimiducid
- P-PSMA-101 CAR-T cells (Single Dose - Part 1c)Treatment being tested
Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen B. Rimiducid may be administered as indicated.
Treatment: P-PSMA-101 CAR-T cells and Rimiducid
- P-PSMA-101 CAR-T cells (Multiple Dose - Part 1d)Treatment being tested
Cyclic administration of ascending dose cohorts, given via intravenous infusions of CAR-T cells, following conditioning chemotherapy regimen B. Rimiducid may be administered as indicated.
Treatment: P-PSMA-101 CAR-T cells and Rimiducid
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
- Record updated
- 17 February 2025